FindTrial
Sign In

To understand the genetics of lupus disease and effect of certain drugs on the treatment of lupus.

Genomic approach to stratify responders vs non-responders to Cyclophosphamide/Hydroxychloroquine/Mycophenolate Mofetil and Rituximab to identify novel class of circulatory miRNA to predict flare episode in systemic Lupus Erythematosus.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/07/054880
Enrollment
60
Registered
2023-07-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M048- Other autoinflammatory syndromes

Interventions

None listed

Sponsors

DEPARTMENT OF HEALTH RESEARCH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Recruit SLE patient moderate to severe flare 2.Patients conformed to the SLE classification criteria by 2019 EULAR /ACR classification . 3.Females or male above 18 or older.

Exclusion criteria

Exclusion criteria: 1.Pregnant women 2.Malignant patients 3.Patients with co-morbidities(diabetes and thyroid) 4.Patient with other autoimmune disease

Design outcomes

Primary

MeasureTime frame
Identification of novel miRNA in lupus flare. 2. Predicting disease flare reduce morbidity and early mortality in SLE patients. 3. miRNA can be used as screening tool for specific and targeted in flare . 4. Differently expressed miRNA with response to drug therapy will provide patient tailored strategy for treatmentTimepoint: 36 months—

Secondary

MeasureTime frame
miRNA can be used as screening tool for specific and targeted in flare . 4. Differently expressed miRNA with response to drug therapy will provide patient tailored strategy for treatmentTimepoint: 24 months—

Countries

India

Contacts

Public ContactDrMukhyaprana M Prabhu

Katurba Medical College Manipal

abhibroto.karmakar@learner.manipal.edu9051469974

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026